Regeneron Pharmaceuticals (REGN)
(Real Time Quote from BATS)
$1,115.92 USD
-15.32 (-1.35%)
Updated Aug 12, 2024 10:06 AM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 101 - 120 ( 594 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reports 4Q and FY 2021; The Triumvirate Strikes Again With Stellar Top-Bottom Beat
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Our Outlook for Regeneron?s Upcoming 4Q 2021 Earnings Report
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Vabysmo Gets FDA Nod for AMD and DME; Regeneron to Counter With High Dose Eylea; Ongoing Phase 3 to Readout in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CHMP to Decide on Expanding Dupixent Approval in Asthmatic Children Aged 6 to 11; Reiterate Buy and $843 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Regeneron Voluntarily Withdraws sBLA for Libtayo in 2L Cervical Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Libtayo?s Dominance in Dermato-Oncology Unlikely To Be Perturbed by New Entrants, in Our View
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Rx for Portfolios, Part 1: Companies With Transformative Clinical Readouts Fast Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PDUFA Date Set For Libtayo-Chemo in 1L NSCLC and Dupixent Improves Prurigo Nodularis; Reiterate Buy and $844 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eylea and REGEN-COV Annual Sales Beat Our Estimates; We Remain Bullish on Regeneron
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ALNY-REGN Seek MHRA Approval in the UK to Initiate a Phase 1 Trial for ALNY-APP in AD and CAA; Reiterate Buy and $844 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Regeneron?s Next-Gen SARS-CoV-2 Antibodies Active Against Omicron and Delta; Set for Clinic in 1Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Regeneron Provides Post-ASH Clinical Development Strategy Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Regeneron Presents Positive Results for Phase 1 Study of REGN5458 in Relapsed or Refractory Multiple Myeloma
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NICE Backs Dupixent as Add-On Therapy Option for Severe Asthma in Patients Ages 12+; Reiterate Buy and $844 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M